Why Is Moderna, Inc. (NASDAQ: MRNA) Stock Up 569% This Year?

What happened

Shares of Moderna, Inc. (NASDAQ: MRNA) closed at $197.28 on September 28, up 569.0% from the December 31, 2025 close of $29.49. This is a share-price change for the same common stock and excludes dividends.

The decisive change arrived on August 19. Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) said a Phase 3 melanoma trial of intismeran plus Keytruda met its recurrence-free survival and distant metastasis-free survival endpoints. The companies called it the first positive Phase 3 result for an individualized neoantigen therapy and for an mRNA cancer therapy.

That result gave investors evidence that the mRNA platform could support a large oncology business rather than remain concentrated in respiratory vaccines. The August 5 FDA approval of MFLUSIVA for adults 50 and older added a fifth approved product and another chance to rebuild seasonal revenue.

This chronology does not prove what caused every dollar of the rally. It shows why the investment question changed from whether the post-pandemic pipeline could produce another important product to whether Moderna, Inc. (NASDAQ: MRNA) can turn positive clinical evidence into approval, individualized manufacturing and durable profit.

Read more: Moderna (MRNA) stock analysis and investment case

The move in numbers

Dividing the September 28 close by the December 31 close and subtracting one gives a 568.97% increase, rounded to 569.0%. Nasdaq reports the same $29.49 and $197.28 endpoints, matching Yahoo to the displayed cent.

Yahoo returned no split event during the period. Both endpoints use the regular Close field in U.S. dollars, so the comparison does not mix an intraday quote with a completed session or substitute a dividend-adjusted total return.

The balance sheet still sets the clock. Moderna, Inc. (NASDAQ: MRNA) reported $6.91 billion of cash and investments at June 30, down from $8.14 billion at year-end. First-half operating cash use improved to $1.16 billion from $1.96 billion a year earlier, but the first-half net loss was $2.13 billion.

The September financing added $2.96 billion of net proceeds from $3.0 billion of 0% convertible notes due in 2032. The initial conversion rate represents 14.25 million shares, or 3.57% of the 399.24 million shares outstanding on July 24. The maximum conversion rate represents 21.01 million shares, or 5.26%.

Those percentages are a gross comparison, not a forecast of dilution. Capped calls, the share price at conversion, settlement choices and repurchases can change the outcome. The calculation still makes the financing tradeoff visible: more runway today can carry a future per-share cost.

Related: Why Is AppLovin Corporation (NASDAQ: APP) Stock Down 54% This Year?

How the business works

Moderna, Inc. (NASDAQ: MRNA) designs medicines by delivering messenger RNA that tells cells to make a target protein. In vaccines, the immune system learns to recognize that protein. In oncology, intismeran is made from mutations found in an individual patient's tumor and can encode up to 34 neoantigens.

The Phase 3 regimen pairs intismeran with Keytruda from Merck & Co., Inc. (NYSE: MRK) after surgery for high-risk melanoma. Merck & Co., Inc. (NYSE: MRK) generally leads trials, while Moderna, Inc. (NASDAQ: MRNA) handles the process and manufacturing work. The collaboration generally shares worldwide development costs and profits or losses equally.

That structure lowers the commercial burden and adds an established oncology partner, but it also means Moderna, Inc. (NASDAQ: MRNA) does not keep all of the economics. Individualized production must also move from tumor sequencing through design, manufacturing and delivery fast enough for routine cancer care.

BioNTech SE (NASDAQ: BNTX) is the clearest direct competitor because BioNTech SE (NASDAQ: BNTX) is also developing individualized mRNA cancer vaccines for solid tumors. The Phase 3 success puts the Moderna, Inc. (NASDAQ: MRNA) partnership ahead on late-stage evidence, while regulatory approval and commercial execution remain unproven.

The initial market is meaningful. The Phase 3 announcement estimated about 112,000 new U.S. melanoma cases and more than 8,500 deaths in 2026. Those figures describe disease burden, not the number of eligible patients, pricing, market share or eventual revenue.

What changed in 2026

The influenza approval expanded the commercial base first. MFLUSIVA is approved for people 50 and older, giving Moderna, Inc. (NASDAQ: MRNA) a product outside COVID-19 and respiratory syncytial virus ahead of the northern-hemisphere flu season.

The melanoma result changed the larger valuation argument. INTerpath-001 enrolled 1,137 patients and met both primary efficacy endpoints. Reuters reported that the announcement added roughly $30 billion to market value as the shares more than doubled that day.

The strongest evidence still came with a major omission. The companies did not disclose the exact hazard ratios or overall-survival result in the announcement. The trial continues for overall survival, and full data were reserved for a medical meeting and regulatory discussions.

The operating base is also thin compared with the new valuation. Second-quarter revenue was $145 million and the net loss was $782 million. The quarter included another setback when the norovirus Phase 3 interim analysis did not meet the prespecified criterion for early success, requiring an additional cohort.

The financing reduces near-term liquidity pressure, but debt does not fix product economics. The investment case now needs oncology evidence, respiratory launches and cost control to arrive together. A strong result in one program cannot erase manufacturing risk, clinical failures elsewhere or the continuing cash burn.

What's next

The next test is the full INTerpath-001 presentation. Investors need the recurrence and metastasis effect sizes, confidence intervals, safety profile, subgroup consistency and any available overall-survival signal. A positive topline statement establishes statistical success, not the size or durability of the benefit.

Then comes regulation and manufacturing. Watch whether regulators accept the filing package, how long individualized production takes, and what failure and remake rates look like. The partnership must make each dose at a cost that supports attractive shared economics.

The next earnings reports should show whether MFLUSIVA gains a meaningful place in the flu market and whether the cash trajectory stays inside management's $4.7 billion to $5.2 billion year-end guide. Revenue growth matters, but cash use and new commitments determine how much runway shareholders are buying.

The bull case strengthens if full melanoma data support approval, personalized manufacturing scales and respiratory launches narrow the losses. It weakens if effect sizes disappoint, overall survival fails, regulation or manufacturing slips, or financing and stock compensation consume too much per-share value. A 569.0% rally makes those unresolved tests more demanding rather than less important.

More from OptimistFi